Silo pharma initiates human factor study of spc-15 for the treatment of ptsd

Study to test effectiveness of instructional system designs (isd) model for intranasal spc-15 englewood cliffs, nj, oct. 11, 2023 (globe newswire) -- silo pharma, inc. (nasdaq: silo) (“the company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced plans to initiate a human factor study of its targeted prophylactic treatment spc-15 for the treatment of post-traumatic stress disorder (ptsd). the study will evaluate the human factor interface and usability of spc-15's intranasal formulation in combination with a nose-to-brain delivery mechanism.
SILO Ratings Summary
SILO Quant Ranking